<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=380349912402896&amp;ev=PageView&amp;noscript=1">
Lumenis logo-2
Optilight + tag line

Join us for the
Virtual Launch Event
May 13th, 2021, 7 pm EST
Learn about the one and only IPL FDA approved for dry eye management

Register today!

Be among the first doctors to lead the Dry Eye revolution!
Hosted by leading experts in the field of DED

The OptiLight virtual launch event is your unique opportunity to be among the first in the world to see OptiLight in action and to be at the cutting-edge of Dry Eye therapy.

ADLER

Dr. Richard Adler 

ronaldo

Dr. Rolando Toyos

Laura

Dr. Laura Periman

epstein

Dr. Arthur B. Epstein

A new dawn for dry eye management,
for you and your patients

16 million people are diagnosed with dry eye in the U.S,
and the number of undiagnosed may be twice as high.

Introducing the first and only IPL FDA approved for dry eye management
• Every element is design driven to allow a precise and comfortable dry eye procedure
• Addresses dry eye disease in an effective and safe in-office therapy
• Light based procedure by Lumenis – the inventors of IPL
• A patented OPT technology that transforms the use of light pulses.

Register today for the exclusive

Optilight + event in white
Register now
white logo

Indication for Use:
Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses.

Treatment with OptiLight is contraindicated for patients with the following conditions in the treatment area:
Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; Prior history of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy.
Patients eyes must be completely occluded during the treatment.
Please refer to the operator manual for a complete list of intended use, contraindications and risks.
Please consult your physician as to whether this procedure is suitable for you.

The following possible side effects can occur following IPL treatments:
Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis.  Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks.